Open Innovation Competition Program for Drug Development by Asahi Kasei Pharma


Asahi Kasei Pharma will launch a grant for joint research or research development mainly on drug discovery seeds and technologies.

  • Open call starts from 5.00 am (GMT) 7th January 2020
  • The deadline is at 8.00am (GMT) 26 February 2020
  • Areas...

InnoHealth China | Call for Ideas & Innovation

The call addresses representatives from research organizations and those from SMEs and start-ups who develop application-oriented technologies and/or processes. 10 tandems - consisting of one representative from the research sector and one from a SME...


What is the secret to successful translation? DFG issues statement and organizes symposium in Berlin with the BIH

Translation is the key focus at the Berlin Institute of Health (BIH). The aim is to transfer promising results from the laboratory to clinical practice, and to use observations from daily clinical routine as inspiration for new research ideas. For...


ProBioGen and Ceva Santé Animale sign an exclusive license agreement to produce vectorised poultry vaccines using AGE1.CR® production technology


ProBioGen AG and Ceva Santé Animale announce the signature of an exclusive license agreement for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR® technology.

ProBioGen and Ceva have a long track record of...


Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy

▪ Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals

▪ Clovis currently planning to file an IND for...


Machine learning improves the diagnosis of patients with head and neck cancers

Researchers from Charité – Universitätsmedizin Berlin and the German Cancer Consortium (DKTK) have successfully solved a longstanding problem in the diagnosis of head and neck cancers. Working alongside colleagues from Technische Universität (TU)...


ProBioGen licenses GlymaxX® Technology to Bayer


ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the GlymaxX® Technology. Under the terms of the agreement, Bayer will...


Eckert & Ziegler: additional production capacities for Gallium-68-Generators released by supervisory authorities

Eckert & Ziegler AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, has been given the manufacturing authorization for additional production lines for its Ge-68/Ga-68-generators (GalliaPharm®). The...

Show more items